Explanipedia

Choroid plexus enlargement in secondary progressive MS: phenotype comparison Open

Samuel Klistorner, Michael Barnett, Chenyu Wang, Anneke van der Walt, Helmut Butzkueven , et al. · 2025

CP enlargement is a progressive feature of MS, not driven by ventricular expansion. In SPMS, it may reflect ongoing inflammation contributing to tissue damage, supporting its role as a biomarker.

YI6 MS outcomes in breast cancer survivors and the influence of chemotherapy Open

Cassie Nesbitt, Paul G. Sanfilippo, Chao Zhu, Serkan Özakbaş, Alexandre Prat , et al. · 2025

3617 Acute and longitudinal magnetic resonance imaging abnormalities in antibody-mediated encephalitis Open

Nabil Seery, Paul Beech, Robb Wesselingh, Mark Schoenwaelder, James Broadley , et al. · 2025

CS11 The effect of high-efficacy therapy on disability in children with multiple sclerosis Open

Sifat Sharmin, Izanne Roos, Anneke van der Walt, Helmut Butzkueven, María Trojano , et al. · 2025

CS6 Retrospective audit of the real-world safety and efficacy profile of eptinezumab for resistant chronic migraine Open

Lakshini Gunasekera, Shuli Cheng, Emma Foster, Shobi Sivathamboo, Terence J. O’Brien , et al. · 2025

3621 Paediatric versus adult-onset neuromyelitis optica spectrum disorder: a multi-centre study Open

Pakeeran Siriratnam, Saif Huda, Paul G. Sanfilippo, Vilija Jokubaitis, Anneke van der Walt , et al. · 2025

YI1 Disability trajectories of women with progressive multiple sclerosis phenotypes after pregnancy Open

Jessica Shipley, Heidi Beadnall, Paul G. Sanfilippo, Helmut Butzkueven, Anneke van der Walt · 2025

CS12 Exploration of an objective measure of cognitive fatigability in multiple sclerosis using the MSReactor digital platform Open

Alexander Sarossy, Melissa Gresle, Chao Zhu, Yi Chao Foong, Jeannette Lechner-Scott , et al. · 2025

The impact of CGRP monoclonal antibodies on cytokine expression in chronic migraine: a cohort study Open

Jason C. Ray, Stuart J. McDonald, Marian Todaro, Josephine Baker, Wei Zhen Yeh , et al. · 2025

Pregnancy-Related Disease Outcomes in Women With Moderate to Severe Multiple Sclerosis Disability Open

Jessica Shipley, Heidi Beadnall, Paul G. Sanfilippo, Wei Zhen Yeh, Dana Horáková , et al. · 2025

Importance Understanding the association between pregnancy and clinical outcomes in women with moderate to severe multiple sclerosis (MS) disability is crucial for guiding family planning and management strategies. Objective To assess peri…

The Hypometabolic State of the Migraine Brain: Is a Ketogenic Diet the Answer? Open

Lakshini Gunasekera, Jason C. Ray, Helmut Butzkueven, Terence J. O’Brien, Elspeth Hutton , et al. · 2025

Background Migraine pathophysiology involves a constellation of metabolic abnormalities. These interlinked contributory factors include mitochondrial dysfunction, an altered gut microbiome, neuroinflammation, oxidative stress, weight imbal…

Migraine in Multiple Sclerosis: Underlying Mechanisms, Shared Symptoms, and Approaches to Management Open

Pavika Thevar, Helmut Butzkueven, Jason C. Ray, Alissandra McIlroy, Elspeth Hutton , et al. · 2025

Background: Migraine affects approximately 50% of people with relapsing-remitting multiple sclerosis (MS). People with MS and migraine also have greater symptom burden and an increased risk of relapse. Understanding the pathophysiology, sy…

Advancing multiple sclerosis management in older adults Open

Anneke van der Walt, Eva Strijbis, Francesca Bridge, Timothy Coetzee, Jennifer Graves , et al. · 2025

COVID-19 Vaccine Boosters in People With Multiple Sclerosis Open

Avani Yeola, Samuel K. Houston, Anupriya Aggarwal, Rashmi Gamage, Vicki E. Maltby , et al. · 2025

Despite not eliciting adequate antibody response in pwMS on IMM-DMT, COVID-19 boosters improve the breadth of the humoral response against SARS-CoV-2 emerging variants. Vaccine protection can be predicted by statistical modeling.

Acute and Long-Term Immune-Treatment Strategies in Anti-LGI1 Antibody–Mediated Encephalitis Open

Nabil Seery, Robb Wesselingh, Paul Beech, Laurie McLaughlin, Tiffany Rushen , et al. · 2025

This study provides Class IV evidence that for patients with anti-LGI1 Ab-mediated encephalitis, rituximab prevents relapses and acute methylprednisolone is associated with favorable outcomes at 12 months.

<span>MGBase</span>: A Global, Observational Registry for Collaborative Research in Myasthenia Gravis Open

Katherine Buzzard, Anneke van der Walt, Helmut Butzkueven, Wen Wen Zhang, Carolina Barnett , et al. · 2025

Introduction/Aims Patient registries are valuable tools for outcomes research in rare diseases such as myasthenia gravis (MG). Existing MG registries are limited by factors including a lack of geographical scope. MGBase has been designed a…

Rituximab Use for Relapse Prevention in Anti-NMDAR Antibody-Mediated Encephalitis Open

Nabil Seery, Robb Wesselingh, Paul Beech, Laurie McLaughlin, Tiffany Rushen , et al. · 2025

This study provides Class IV evidence that rituximab delays relapses in patients with anti-NMDAR antibody-mediated encephalitis.

Brain health – time matters: multiple sclerosis, neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and related conditions. 2024 report Open

Helmut Butzkueven, Sofia Arkelsten, Cristoforo Comi, Kathleen Costello, Michael Devlin , et al. · 2025

These policy recommendations could ensure the best possible outcomes by a person-centred approach to care, regardless of geographic or economic barriers. The key is to start somewhere, as even small changes can make a difference for indivi…

Progression independent of relapse activity and relapse-associated worsening in seronegative NMOSD: an international cohort study Open

Pakeeran Siriratnam, Saif Huda, Anneke van der Walt, Paul G. Sanfilippo, Sifat Sharmin , et al. · 2025

Prioritising patient involvement in patient reported outcome measures– a PROMising way to improve headache care Open

Lakshini Gunasekera, Jason C. Ray, Neha Kaul, Helmut Butzkueven, Elspeth Hutton , et al. · 2025

Choroid Plexus Enlargement in Secondary Progressive MS: phenotype comparison Open

Samuel Klistorner, Michael D. Barnett, Chenyu Wang, Anneke van der Walt, Helmut Butzkueven , et al. · 2025

Background The choroid plexus (CP) is increasingly recognised as a contributor to chronic inflammation in multiple sclerosis (MS). While CP enlargement is reported in early MS, its role in secondary progressive MS (SPMS) is poorly understo…

Long-term acceptability of MSReactor digital cognitive monitoring among people living with multiple sclerosis Open

Daniel Merlo, Johnson Ja, Yi Chao Foong, Chao Zhu, Melissa Gresle , et al. · 2025

Background: Monitoring of cognition in multiple sclerosis (MS) is critical. Traditional cognitive testing is resource intensive and insensitive to subtle changes. Digital tests could address this need; however, their long-term usability re…

Longitudinal Trajectories of Digital Cognitive Biomarkers for Multiple Sclerosis Open

Yi Chao Foong, Daniel Merlo, Melissa Gresle, Chao Zhu, Katherine Buzzard , et al. · 2025

Background Cognitive impairment is one of the most common and debilitating symptoms of relapsing–remitting multiple sclerosis (RRMS). Digital cognitive biomarkers require less time and resources and are rapidly gaining popularity in clinic…

First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis Open

Simona Toscano, Tim Spelman, Serkan Özakbaş, Raed Alroughani, Clara Grazia Chisari , et al. · 2025

Adaptive transformer modelling of density function for nonparametric survival analysis Open

Xin Zhang, Deval Mehta, Yanan Hu, Chao Zhu, David Darby , et al. · 2025

Survival analysis holds a crucial role across diverse disciplines, such as economics, engineering and healthcare. It empowers researchers to analyze both time-invariant and time-varying data, encompassing phenomena like customer churn, mat…

Brain Health – Time Matters: Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder (MOGAD), Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) and Related Conditions. 2024 Report Open

Helmut Butzkueven, Gavin Giovannoni, Sofia Arkelsten, Gıancarlo Comı, Kathleen Costello , et al. · 2025

Persistent progression independent of relapse activity in multiple sclerosis Open

Chao Zhu, Zhen Zhou, Tomáš Kalinčík, Izanne Roos, Katherine Buzzard , et al. · 2025

Patients with relapsing-remitting multiple sclerosis (RRMS) may experience disability progression independent of relapse activity (PIRA), which can be an early sign of secondary progressive MS (SPMS). We defined persistent PIRA as ongoing …

Longitudinal trajectories of digital upper limb biomarkers for multiple sclerosis Open

Yi Chao Foong, Daniel Merlo, Melissa Gresle, Chao Zhu, Katherine Buzzard , et al. · 2024

Background Upper limb dysfunction is a common debilitating feature of relapsing‐remitting multiple sclerosis (RRMS). We aimed to examine the longitudinal trajectory of the iPad®‐based Manual Dexterity Test (MDT) and predictors of change ov…

De-escalating and discontinuing disease-modifying therapies in multiple sclerosis Open

G. Androdias, Jan D. Lünemann, Élisabeth Maillart, Maria Pia Amato, Bertrand Audoin , et al. · 2024

The development of disease-modifying therapies (DMTs) for the treatment of multiple sclerosis (MS) has been highly successful in recent decades. It is now widely accepted that early initiation of DMTs after disease onset is associated with…

Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network Open

Johannes Lorscheider, Alessio Signori, Suvitha Subramaniam, Pascal Benkert, Sandra Vukusic , et al. · 2024

Background Effectiveness of disease-modifying treatment (DMT) in people affected by primary progressive multiple sclerosis (PPMS) is limited. Whether specific subgroups may benefit more from DMT in a real-world setting remains unclear. Our…

Helmut Butzkueven YOU? Author Swipe